Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Elon Musk Wins Reinstatement of Historic Tesla Pay Package After Delaware Supreme Court Ruling 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role 
Seatrium Reaches $475 Million Settlement With Maersk Over Offshore Wind Vessel Project 
PHILADELPHIA, Oct. 10, 2016 -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated gene therapy company seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering treatments, announced today that members of company management and a principal investigator will participate in the following American Association of Ophthalmology (AAO) Annual Meeting events between Oct. 13 and Oct. 18:
2016 Ophthalmology Innovation Summit, or OIS@AAO, at the Hyatt Regency Chicago
- Jeffrey D. Marrazzo, chief executive officer, will participate in the Gene Therapy Breakfast Break-Out Panel discussion on Thursday, Oct. 13, at 7:30 a.m. (CDT)
Retina Days Subspecialty Meeting, at the McCormick Center in Chicago
- Albert M. Maguire, M.D., professor of ophthalmology at the Perelman School of Medicine of the University of Pennsylvania, will talk about “Gene Therapy for Leber Amaurosis Type 2 – Clinical Trials Results,” including data from the pivotal Phase 3 trial of voretigene neparvovec on Friday, Oct. 14, at 12:13 p.m. (CDT)
Additionally, the company will have a booth presence in the McCormick Center exhibit hall throughout the AAO meeting. Visit us at Booth 1980.
About Spark Therapeutics
Spark Therapeutics, a fully integrated gene therapy company, is seeking to transform the lives of patients with debilitating genetic diseases by developing potential one-time, life-altering treatments. Spark Therapeutics’ validated gene therapy platform is being applied to a range of clinical and preclinical programs addressing serious genetic diseases, including inherited retinal diseases, liver-associated diseases, such as hemophilia, and neurodegenerative diseases. Spark Therapeutics’ validated platform has successfully delivered proof-of-concept data with investigational gene therapies in the eye and liver. Spark Therapeutics’ most advanced product candidate, voretigene neparvovec (formerly referred to as SPK-RPE65), which has received both breakthrough therapy and orphan product designations, has reported top-line results from a pivotal Phase 3 clinical trial for the potential treatment of a rare blinding condition. Spark Therapeutics’ hemophilia franchise has two lead assets: SPK-9001 in a Phase 1/2 trial for hemophilia B and SPK-8011, a preclinical candidate for hemophilia A. To learn more, please visit www.sparktx.com.
Spark Therapeutics Corporate Contacts Stephen W. Webster, Chief Financial Officer Daniel Faga, Chief Business Officer (855) SPARKTX (1-855-772-7589) Media Contact Dan Quinn Ten Bridge Communications (781) 475-7974 [email protected]
